Boehringer Ingelheim's Ofev scores FDA nod as first treatment for rare lung disease

9th September 2019 Uncategorised 0

Boehringer Ingelheim rode rare lung disease med Ofev to serious sales growth last quarter, and it’s looking to keep that trend going. Could a new, competition-free lung disease indication be the boost the drugmaker is looking for? The FDA Friday green-lighted Ofev in an indication without any other approved drugs.

More: Boehringer Ingelheim's Ofev scores FDA nod as first treatment for rare lung disease
Source: fierce